Intestinal Akkermansia Muciniphila in Prostate Cancer - Trial NCT06242509

Timeline & Enrollment

Primary Outcome

Relative abundance of Akkermansia muciniphila

Summary

Prostate cancer has the highest incidence and is the second leading cause of cancer death in
 men in western countries. Androgen deprivation therapy is the backbone treatment. However,
 after a latency hormone sensitive prostate cancer (HSPC) usually progresses to
 castration-resistant prostate cancer (CRPC) requiring treatments including next generation
 hormonal therapies with Abiraterone Acetate (AA). This, with limited survival.
 
 A particularly challenging area of interest to improve outcome in cancer is the interaction
 between the microbiome and anti-cancer therapies. Emerging data demontrate in pre-clincal
 studies that prostate cancer alters the microbiota, with loss of diversity and depletion of
 beneficial bacteria including A. muciniphila. In the other hand, Androgen deprivation
 therapy, reverses these effects. Specifically, in advanced disease with castration-resistant
 prostate cancer (CRPC), it has been shown in small studies that Abiraterone Acetate, can
 modulate patient-associated gastro-intestinal microbiota through promoting the growth of A.
 muciniphila.
 
 The goal of our study is to confirm that AA could promote fecal Akkermansia muciniphila
 growth and to use the enrichment of fecal Akkermansia muciniphila as a minimally invasive
 biomarker of response to AA in first line metastatic CRPC.

ICD-10 Classifications